This year’s Global Biosimilars Week awareness campaign from the IGBA is less than a month away, with the event running from Oct. 19-24 and focusing on realizing the global value of biosimilars.
Dsm-firmenich spent two decades working to add BEMT to the OTC sunscreen monograph — but the path it cleared for future UV ...
Regulators are warming to real-world evidence in device submissions, but the FDA has identified a recurring failure mode: ...
FDA's drug review chief wants artificial intelligence to do what regulators can no longer do after a wave of retirements: ...
Corcept Therapeutics’ Lifyorli and Impact Therapeutics’ Sepalna are on track for pan-EU marketing approval to treat patients ...
The FDA granted full approval to Lilly’s oral SERD imlunestrant, expanding its label from monotherapy to include combination ...
With Fayuvi now approved, Ultragenyx turns to building treatment-center capacity, securing payer access and identifying ...
The two companies are looking to catch up with rivals in AI-assisted drug discovery, and want to help train AI to think like ...
After the European Medicines Agency upheld its negative opinion for Xervyteg, MaaT Pharma said it was evaluating strategic funding options to strengthen the drug's evidence package and pursue future ...
New treatments from AstraZeneca and Xcovery/Betta Pharmaceuticals for generalized myasthenia gravis and ALK-positive advanced non-small cell lung cancer, respectively are on track for EU-wide ...
Aurobindo's generic equivalent of Teva's branded QVAR inhaler has gained approval from the US regulator, following ...
The company filed for approval of the drug in focal seizures, but it paused new enrollment in psychiatric studies due to adverse events.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results